International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.
International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.
Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.
Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.
Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.
Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.
Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.
International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.
Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.
Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.
Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.
An International Open Access Journal Devoted to General Medicine.
Successful treatment with tepotinib followed by pembrolizumab in pulmonary pleomorphic carcinoma harbouring a MET exon 14 skipping mutation: A case report
Pulmonary pleomorphic carcinoma (PPC) is a subtype of sarcomatoid carcinoma that accounts for 0.1‑0.3% of all lung cancer cases. PPC is typically resistant to chemotherapy and radiotherapy, and no standard treatment protocols are currently established. Moreover, to the best of our knowledge, the effectiveness of the MET inhibitor tepotinib in the treatment of PPC has not yet been reported. Herein, the present study describes the case of a 75‑year‑old woman with PPC harbouring a MET exon 14 skipping mutation who was successfully treated with tepotinib as first‑line systemic therapy, followed by pembrolizumab as subsequent immune checkpoint inhibitor therapy. Although the tumour relapsed 4 months postoperatively, treatment with tepotinib resulted in a favourable response and subsequent pembrolizumab therapy achieved a durable response. This case suggests that patients with sarcomatoid carcinoma, which is generally associated with a poor prognosis, may experience improved outcomes with the use of molecular targeted therapies and immune checkpoint inhibitors.